IR
Superintel
OverviewMarketsWatchlist
© 2026 IR SuperintelMethodologyContact

Candel Therapeutics Inc

CUSIP: 137404959 | 5 institutional holders

Quarters

Q3 2026Q2 2026Q1 2026Q4 2025Q3 2025
CompareDetailedHistoricalFundsOptionsShort Interest13D/13GPeersTargetingTrading SummaryProfile